名称 | RG7834 |
描述 | RG7834 (RO 7020322) is a highly selective and orally bioavailable inhibitor of HBV, targeting HBsAg, HBeAg, and HBV DNA with IC50s of 2.8 nM, 2.6 nM, and 3.2 nM, respectively, in dHepaRG Cells. |
体外活性 | RG7834 ((S)-(+)-64) is a highly selective and orally bioavailable inhibitor of HBV, potently inhibiting HBV antigens (HBsAg and HBeAg) and HBV DNA with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG cells. RG7834 exhibits no activity against CYP3A4, CYP2D6, CYP2C9 (IC50s >50 μM) or the hERG channel. |
体内活性 | In HBV-infected human liver chimeric uPA-SCID mice,RG7834 shows anti-HBV efficacy. RG7834 (2, 14.5 mg/kg, p.o.) exhibits good oral bioavail ability, and with a half-life of 4.9 h in mice. |
存储条件 | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 125 mg/mL (311.37 mM), Sonication is recommended.
|
关键字 | Hepatitis B virus | RO7020322 | RG 7834 | inhibit | Inhibitor | RG-7834 | RG7834 | RO-7020322 | HBV |
相关产品 | Doxorubicin hydrochloride | Osthole | RO8191 | Cetylpyridinium Chloride | Tenofovir Disoproxil Fumarate | Thiamine hydrochloride | 4,5-Dicaffeoylquinic acid | Vebicorvir | 4-Hydroxyacetophenone | Telbivudine | Tenofovir | Bifendate |
相关库 | 经典已知活性库 | ReFRAME 相关化合物库 | 抗病毒库 | 药物功能重定位化合物库 | 抑制剂库 | 临床期小分子药物库 | 已知活性化合物库 |